Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.
Inflammation may influence response to pharmacotherapy. We investigated the effect of inflammation on response to sotalol, a beta-adrenergic receptor and potassium channel antagonist. Racemic sotalol (40 mg kg(-1)) was administered to healthy, acutely (interferonalpha 2a-induced) and chronically (Mycobacterium butyricum-induced adjuvant arthritis) inflamed male Sprague-Dawley rats (n=4 - 6/group). Another group of interferon-treated rats received 3 mg kg(-1) of anti-TNF antibody infliximab. Electrocardiogram (ECG) recorded and plasma sotalol concentration monitored for 6 h. The study was repeated in acutely inflamed rats following administration of stereochemically pure individual sotalol enantiomers [40 mg kg(-1) S (potassium channel blocker) or 20 mg kg(-1) R (beta-adrenergic/potassium channel blocker)]. Chronic arthritis was readily evident. Acute arthritis was associated with elevated segmented neutrophils and increased plasma nitrite and tumour necrosis factor (TNF) concentrations. Sotalol affected ECG in all rats. In both inflamed groups, however, response to sotalol in prolongation of QT interval (potassium channel sensitivity) was reduced. The effect of PR interval (beta-adrenergic activity) was also reduced following administration of the racemate and R-enantiomer. No significant differences in pharmacokinetics were observed between control and inflamed rats. Infliximab reduced nitrite and TNF concentrations and reversed the effect of acute inflammation on both PR and QT intervals. The reduced electrocardiographic responses to sotalol is likely due to the influence of inflammation on the action of the drug on both beta-adrenergic and potassium channel receptors secondary to over-expression of pro-inflammatory cytokines and/or nitric oxide. Our observation may have therapeutic consequences in all conditions where inflammatory mediators are increased.
Kulmatycki
K M
KM
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada T6G 2N8.
Abouchehade
K
K
Sattari
S
S
Jamali
F
F
D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D019540:Area Under Curve; D001682:Biological Availability; D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography / Q000187:drug effects; D007249:Inflammation / Q000139:chemically induced / Q000473:pathology*; D000069285:Infliximab; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008297:Male; D009161:Mycobacterium / Q000737:chemistry; D009569:Nitric Oxide / Q000097:blood; D026902:Potassium Channel Blockers; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D013015:Sotalol / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000319:Adrenergic beta-Antagonists; D000911:Antibodies, Monoclonal; D016207:Cytokines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D026902:Potassium Channel Blockers; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D013015:Sotalol; D000069285:Infliximab